Overview

A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy

Status:
Completed
Trial end date:
2018-07-18
Target enrollment:
Participant gender:
Summary
The goal of this study is to identify changes in cells that are related to the treatment with Cat-PAD (ToleroMune Cat).
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
Circassia Limited